Investigating how ACER2 affects breast cancer treatment resistance and spread
Role of ACER2 in cancer chemoresistance and metastasis
This study is looking at how a protein called ACER2 affects breast cancer patients who are receiving chemotherapy before surgery, with the goal of finding ways to make treatments work better and help prevent the cancer from spreading.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-10861901 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of alkaline ceramidase 2 (ACER2) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). The study aims to explore how ACER2 may contribute to the development of chemoresistance and metastasis, potentially making treatments less effective. By examining the biochemical pathways involved, particularly the conversion of ceramide to sphingosine-1-phosphate, the researchers hope to identify new therapeutic strategies that could enhance the efficacy of breast cancer treatments. Patients may benefit from insights that could lead to improved treatment options and outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients, particularly those receiving neoadjuvant chemotherapy.
Not a fit: Patients with non-breast cancers or those not undergoing chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer, reducing the risk of chemoresistance and metastasis.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Mao, Cungui — State University New York Stony Brook
- Study coordinator: Mao, Cungui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.